Molecular Partners (NASDAQ:MOLN) and Coherus Oncology (NASDAQ:CHRS) Critical Analysis

Molecular Partners (NASDAQ:MOLN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Insider and Institutional Ownership

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Molecular Partners and Coherus Oncology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65 million	28.94	-$74.41 million	($1.71)	-2.37
Coherus Oncology	$42.17 million	4.30	$168.02 million	($1.03)	-1.14

Coherus Oncology has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Molecular Partners and Coherus Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Molecular Partners and Coherus Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1	1	2	0	2.25
Coherus Oncology	1	0	2	0	2.33

Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 106.79%. Coherus Oncology has a consensus price target of $11.00, indicating a potential upside of 836.17%. Given Coherus Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Molecular Partners.

Volatility and Risk

Molecular Partners has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Summary

Coherus Oncology beats Molecular Partners on 9 of the 13 factors compared between the two stocks.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

About Coherus Oncology

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.